On Oct 30, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical (BMRN.US)$, with price targets ranging from $78 to $122.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and maintains the target price at $112.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and adjusts the target price from $120 to $109.
Citi analyst David Lebowitz maintains with a hold rating, and adjusts the target price from $93 to $81.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $86.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $119 to $106.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin experienced a robust quarter, with a slight increase in its guidance for both revenue and earnings. Analysts believe that the value of the company's enzyme replacement therapy business may match or exceed the current share price. Additionally, the anticipation of BMN333 entering clinical trials in early 2025 is seen as potentially pivotal for BioMarin, not only in maintaining its position in the achondroplasia market but also expanding into other indications where Voxzogo is under investigation.
BioMarin's Q3 financial outcomes surpassed expectations on both the top and bottom lines, and there was a slight increase in the forecast for fiscal 2024 across all principal metrics. Although Voxzogo's performance fell short of projections, this was balanced by stronger-than-anticipated results from various other offerings within the company's enzyme replacement therapy portfolio.
The firm recognizes an appealing opportunity for investment at the present share price, highlighting BioMarin's solid foundational business and the prospects for significant operating margin growth in the coming years.
The latest financials and pipeline updates from BioMarin for the third quarter of 2024 were largely as anticipated. It's positive to note a slight increase in the guidance for 2024. However, the perceived deceleration in growth for Voxzogo, which is considered crucial to BioMarin's success, may not meet investor expectations.
Here are the latest investment ratings and price targets for $Biomarin Pharmaceutical (BMRN.US)$ from 15 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月30日，多家华尔街大行更新了$拜玛林制药 (BMRN.US)$的评级，目标价介于78美元至122美元。
摩根士丹利分析师Vikram Purohit维持买入评级，维持目标价112美元。
摩根大通分析师Jessica Fye维持买入评级，并将目标价从120美元下调至109美元。
花旗分析师David Lebowitz维持持有评级，并将目标价从93美元下调至81美元。
巴克莱银行分析师Gena Wang维持买入评级，维持目标价86美元。
瑞士银行分析师Eliana Merle维持买入评级，并将目标价从119美元下调至106美元。
此外，综合报道，$拜玛林制药 (BMRN.US)$近期主要分析师观点如下：
BioMarin经历了一个强劲的季度，营收和收益的预期均略有增加。分析师认为公司的酶替代疗法业务价值可能与当前股价相匹配或超过。此外，预计BMN333将在2025年初进入临床试验，被视为BioMarin的潜在关键一步，不仅有助于在骨发育不全市场上维持地位，还有望扩大到Voxzogo正在接受研究的其他适应症。
BioMarin的第三季度财务表现超出预期，无论是销售额还是利润方面都有小幅增长，并且在所有主要指标上对2024财年的预测也略有增加。虽然Voxzogo的表现未达预期，但公司酶替代疗法组合中其他各项产品的业绩强于预期，起到了平衡作用。
该公司意识到现在的股价提供了一个投资吸引力机会，突显了BioMarin稳固的基础业务以及未来几年营业利润率增长的前景。
关于2024年第三季度的最新财务状况和BioMarin的产品线更新基本符合预期。值得一提的是，对2024年的预期指引略有增加。然而，考虑到对BioMarin成功至关重要的Voxzogo增长放缓，可能无法达到投资者的预期。
以下为今日15位分析师对$拜玛林制药 (BMRN.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
